Myeloproliferative Neoplasms

>

Latest News

Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.
Metformin Use Reduces MPN Diagnosis Risk

May 26th 2024

Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.

Results from the phase 3 MOMENTUM trial led momelotinib to being approved by the European Commission for patients with myelofibrosis plus anemia and splenomegaly.
European Commission Approves Momelotinib for Myelofibrosis/Anemia

January 29th 2024

Dose reductions and interruptions of navitoclax plus ruxolitinib in the TRANSFORM-1 trial appear to be mostly due to thrombocytopenia, according to Naveen Pemmaraju, MD.
Navitoclax Combo Significantly Reduces Spleen Volume in Myelofibrosis

December 10th 2023

Differentiation Between 2 Types of MPNs Distinguished in AI Algorithm
Differentiation Between 2 Types of MPNs Distinguished in AI Algorithm

December 9th 2023

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.
CHMP Shares Positive Opinion of Momelotinib for Myelofibrosis/Anemia

November 13th 2023

Video Series
Video Interviews
Podcasts

More News